ClinicalTrials.gg
RecruitingNCT05733520I-CARE 2Updated Nov 24, 2025

I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms

An interventional study of Brain CareNotes and Dementia Guide Expert in Caregiver Burden and Alzheimer Disease, sponsored by Indiana University. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Indiana University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Caregiver Burden by Indiana University — 3 open to participants now, 4 under way, none of them phase 3. Caregiver Burden · Indiana University.

Planned enrollment
3rd of 10
184 · median 60
Started
2023
with 1 other
No phase
10 of 10
3 open now
Registered
7th of 10
by date

Among the 10 studies in Caregiver Burden by Indiana University, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2023, is one of 10 with no phase, and was the 7th registered.

Caregiver Burden

503 studies on the registry are indexed under Caregiver Burden; 166 are open to participants now.

Browse Caregiver Burden studies →

Open to participants now

3 of the 10 studies in Caregiver Burden by Indiana University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 90 Caregiver Burden studies recruiting now, 69 (77%) set no upper age limit and 7 (8%) stop at 75 or younger; 8 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Caregiver Burden by Indiana University, or all of them as a file.
02

Study summary

This study is a randomized, controlled trial (RCT) to evaluate the effect of Brain CareNotes (a mobile health application) on the burden experienced by unpaid caregivers of patients with dementia and on the behavioral and psychological symptoms of dementia (BPSD) displayed by care recipients. Over 39 months, the trial will enroll 184 caregivers of community-dwelling patients diagnosed with Alzheimer's disease or a related dementia (ADRD). Caregivers will be randomized to use the Brain CareNotes app or an attention control education-only app for 12 months, with usage reminders.

Read the detailed description

This study is a hybrid efficacy-effectiveness RCT to evaluate the effect of Brain CareNotes on unpaid caregiver burden and patient BPSD. Over 39 months, the trial will enroll 184 caregivers. Participants will be randomized to use the Brain CareNotes app or an attention control education-only app (Dementia Guide Expert) for 12 months.

The primary objective is to test the effect of Brain CareNotes on a) caregiver burden and b) patient BPSD at 12 months. The investigators hypothesize that caregiver burden and patient BPSD will be lower among those participants randomized to the Brain CareNotes intervention compared to those randomized to the education-only attention control app at 12 months. The primary, powered outcomes are calculated using the caregiver-reported Neuropsychiatric Inventory (NPI); the total NPI score measures patient BSPD and the caregiver distress sub-score measures caregiver burden. The investigators will obtain NPI responses from caregivers at baseline, six, and 12 months.

The secondary objective is to test the effect of Brain CareNotes on a) caregiver depressive symptoms and b) patient and caregiver acute care utilization at 12 months. The investigators hypothesize that participants randomized to the Brain CareNotes intervention will have lower caregiver depressive symptoms and decreased acute care utilization compared to those randomized to the control app. For caregiver depressive symptoms, investigators will use the researcher-administered Patient Health Questionnaire-9 (PHQ-9) at baseline, six, and 12 months. Acute care utilization data will be obtained from self-reports or Indiana's statewide Health Information Exchange (HIE), known as the Indiana Network for Patient Care (INPC), to identify both caregivers' and patients' hospital and ER visits that occurred within 12 months of enrollment.

03

Conditions studied

  • Caregiver Burden
  • Alzheimer Disease

Keywords

  • Alzheimer's disease and related dementias
  • Caregiver
  • Caregiver Burden
  • Behavioral and psychological symptoms of dementia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Caregiver Inclusion Criteria:

  • Self-identified primary unpaid caregiver of a person diagnosed with ADRD (at any stage) who are:
  • Receiving primary care and
  • Community-dwelling;
  • English literate;
  • Age ≥ 18 years

Caregiver Exclusion Criteria:

  • Care recipient is a permanent resident of an extended care facility (nursing home);
  • Involvement in another clinical trial that would prevent or interfere with study objectives;
  • Sensory or other impairment prohibiting the use of a mobile touchscreen device or other study activity (after correction)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
184 participants (estimated)

Study arms

  • Experimental
    Brain CareNotes App

    Behavioral: Brain CareNotes

  • Active comparator
    Attention Control App

    Behavioral: Dementia Guide Expert

Interventions

  • BehavioralBrain CareNotes

    The Brain CareNotes mobile telehealth app is used by unpaid caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.

  • BehavioralDementia Guide Expert

    Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains "evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services."

06

What researchers measure

Primary outcomes

  1. Caregiver Burden

    The burden experienced by caregivers caused by their caregiving responsibilities measured by the Neuropsychiatric Inventory (NPI) caregiver distress sub-score. The distress score is calculated by adding the distress score for each of the 12 items of the NPI. A score of 0 would indicate that the BPSD cause no distress while a score of 60 would indicate that each symptom causes severe distress for the caregiver.

    Time frame: 12 months

  2. Patient BPSD

    Behavioral (e.g. agitation, aggression, wandering) and psychological (e.g. delusions, hallucinations) symptoms of dementia as measured by the Neuropsychiatric Inventory (NPI). The NPI is a 12-item questionnaire. The total score is calculated by adding the product of the frequency and severity of those 12 items. A score of 0 would indicate that no symptoms are present while a score of 144 would indicate that all symptoms are present at the highest level of frequency and severity.

    Time frame: 12 months

Secondary outcomes

  1. Caregiver Depressive Symptoms

    Caregiver depression as measured by the Patient Health Questionnaire (PHQ)-9. The PHQ-9 is a 9-item questionnaire using a 0-3 rating scale. Scores range from 0-27. A total score of 0 represents no depression, while score of 5, 10, 15, and 20 serve as cut points for mild, moderate, moderately severe, and severe depression, respectively.

    Time frame: 12 months

  2. Caregiver Acute Care Utilization

    Caregiver visits to emergency rooms, hospitals, or inpatient diagnoses. Obtained from caregiver self-reports or medical records.

    Time frame: 12 months

  3. Patient Acute Care Utilization

    Patient visits to emergency rooms, hospitals, or inpatient diagnoses. Obtained from caregiver self-reports or medical records.

    Time frame: 12 months

Other outcomes

  1. Caregiver Self-efficacy

    Caregiver perceived self-efficacy as measured using the Revised Scale for Caregiving Self-Efficacy. It consists of 3 sections each with five items. Participants rank self-efficacy on a scale of 0-100 for each item, with a higher score representing greater confidence. Thus, a high total score represents greater self-efficacy.

    Time frame: 12 months

  2. Caregiver Social Support

    Caregiver perceived social support measured using the Multidimensional Scale of Perceived Social Support (MSPSS). The MSPSS is a 12-item questionnaire using a 7-point Likert scale where 1=very strongly disagree and 7=very strongly agree. Scores range from 12-84. A low score represents minimal social support while a high score represents a great level of perceived social support.

    Time frame: 12 months

  3. System Usability Scale

    10-item standardized survey of user-reported technology usability, based on revised System Usability Scale, with scale score computed ranging from 0-100, with 100 indicating highest possible perceived usability.

    Time frame: 12 months

  4. Behavioral Intention Questionnaire

    A 4-item questionnaire assessing a user's intention to use a technology in the near future. Scores range from 0-24 with a high score representing greater intention to use the technology.

    Time frame: 12 months

  5. App Use

    Usage logs of app use over time.

    Time frame: 12 months

07

Study locations

2 of 2 sites recruiting
  • IU Health
    Indianapolis, Indiana 46202, United States
    Recruiting
    • Malaz Boustani, MD · Contact
  • Community Health Network
    Indianapolis, Indiana 46203, United States
    Recruiting
    • Molly Campbell, DNP · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Jul 2027, 50 months after the start.

Of 285 non-industry interventional studies with no phase under Caregiver Burden, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 31. This study's planned 50 months is above that.

Counting every sponsor, half of 294 studies reached it within 16 months; a quarter within 7 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2023
First posted
Feb 17, 2023
StartActual
May 30, 2023
Primary completionEst.
Jul 30, 2027
CompletionEst.
Jul 30, 2027
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05733520
Lead sponsor
Indiana University
Collaborators
National Institute on Aging (NIA), Regenstrief Institute, Inc.
Responsible party
Richard Holden (Department Chair, Dean's Eminent Scholar & Professor, Indiana University) — Principal investigator
First posted
Feb 17, 2023
Start date
May 30, 2023
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Nov 24, 2025

Study contacts

Miriam J Rodriguez, PhD
Contact
mijrodri@iu.edu
(812) 856-1661
Jordan R Hill, PhD
Contact
jrh6@iu.edu
812-856-5032
Richard J Holden, PhD
principal investigator · Indiana University
Malaz Boustani, MD
principal investigator · Indiana University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion